Results 231 to 240 of about 1,320,527 (284)

Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real‐world observational study

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1524-1532, September 2026.
This real‐world observational study enrolled 256 patients with type 2 diabetes and chronic kidney disease (T2D‐CKD). After 12 months of finerenone treatment, 45 patients completed follow‐up. Finerenone was associated with significant improvements in insulin resistance markers (HOMA‐IR, TyG index), lipid profile (LDL‐C), glycemic control (HbA1c), and ...
Xin Zhao, Bohan Liu, Ran Sun, Yaxuan Shi, Ya Liu   +4 more
wiley   +1 more source

A Randomized trial assessing Efficacy and safety of Mineralocorticoid receptor Antagonist therapy compared to Standard antihypertensive Therapy in hypErtension with low Renin (REMASTER): rationale and study design. [PDF]

J Hum Hypertens
Shah SS, Gwini SM, Stowasser M, Reid CM, Young MJ, Fuller PJ, Yang J.   +6 more
europepmc   +1 more source

Developing a machine learning model to predict renal function decline within three years using one‐year longitudinal data in patients with type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1506-1513, September 2026.
We developed a machine learning model to predict renal function decline in patients with type 2 diabetes and preserved kidney function. Using one year of routine clinical data, the model forecasts eGFR decline over three years, enabling early identification of high‐risk patients and supporting timely, targeted therapeutic interventions.
Mari Kaneda, Shu Meguro, Kaiken Kimura, Youichiro Harada, Makoto Enomoto, Kaori Hayashi   +5 more
wiley   +1 more source

Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1625-1633, September 2026.
ABSTRACT Aims/Introduction To demonstrate noninferiority of continued sodium zirconium cyclosilicate therapy versus a potassium‐restricted diet in achieving normokalemia at Visit 7 (Days 28–42) in individuals with type 2 diabetes and hyperkalemia, using a noninferiority margin of −10 percentage points (one‐sided α = 0.025).
Masahide Hamaguchi, Junya Hironaka, Hiroshi Okada, Mari Yoneda, Ayaka Kobayashi, Yoshitaka Hashimoto, Aya Kitae, Noriyuki Kitagawa, Akio Kishi, Michiyo Ishii, Mai Asano, Masahiro Yamazaki, Toru Tanaka, Hanako Nakajima, Eiko Sato, Michiaki Fukui   +15 more
wiley   +1 more source

Salt Intake and Kidney Outcomes in Older Adults With Chronic Kidney Disease: A Stage‐Specific Cohort Study

Nephrology, Volume 31, Issue 9, September 2026.
ABSTRACT Aim In patients with chronic kidney disease (CKD), salt restriction has been shown to lower blood pressure and proteinuria and to provide kidney protective effects. However, the benefit of salt restriction in older adults with CKD remains unclear, particularly in advanced stages.
Hiroaki Miyauchi, Tatsuhiko Azegami, Takashin Nakayama, Chisato Mitsue, Hirotaka Shibata, Kaori Hayashi   +5 more
wiley   +1 more source

Protective Effects of Selective Mineralocorticoid Receptor Antagonist in Alport Syndrome on Top of Renin-Angiotensin-System/ Sodium-Glucose Transporter 2 Blockade. [PDF]

Kidney Int Rep
Song ZR, Li Y, Zhang H, Zhou XJ.
europepmc   +1 more source

Supraphysiological Glucocorticoid Doses and Pitfalls of Annual Biomarker Monitoring in Adults With CAH

Clinical Endocrinology, Volume 105, Issue 3, Page 360-362, September 2026.
Jakob Bolinder, Oskar Ragnarsson, Gudmundur Johansson   +2 more
wiley   +1 more source